APOA2 and pancreas disorder: To verify the truncation of ApoAII in patients with pancreatic diseases, we newly produced a polyclonal antibody that specifically recognizes the ApoAII peptide with an intact C-terminus (-ATQ), but not that with a cleaved C-terminus (-AT) (Fig. 6A), as well as a polyclonal antibody that specifically recognizes the Apo-AII peptide with a cleaved (-AT) C-terminus, but not that with an intact (-ATQ) C-terminus (Fig. 6B).